Boston, Mass. – May 11, 2020 – Akouos, a precision genetic medicine company developing gene therapies to potentially restore, improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 23rd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be held virtually May 12-15, 2020.
Two poster presentations will highlight Akouos’s use of AAVAnc80 vector technology and its potential to address many forms of hearing loss. Presentation details are as follows:
Title: Use of the Adeno-Associated Viral Anc80 (AAVAnc80) Vector for the Development of Precision Genetic Medicines to Address Hearing Loss
Date and Time: Tuesday, May 12, 2020 5:30 PM – 6:30 PM (EST)
Title: Enabling Temporal Control of Gene Expression in the Inner Ear after AAVAnc80 Vector Mediated Delivery
Date and Time: Wednesday, May 13, 2020 5:30 PM – 6:30 PM (EST)
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. For more information, please visit www.akouos.com.
About AAVAnc Technology
The Ancestral AAV (AAVAnc) platform was developed in the laboratory of Luk Vandenberghe, Ph.D., director of the Grousbeck Gene Therapy Center at Harvard Medical School. AAVAnc technology uses computational and evolutionary methods to predict novel conformations of the adeno-associated viral particle. AAVAnc80, one of approximately 38,000 AAVAnc vectors, has demonstrated preliminary safety and effective gene delivery in both mice and non-human primates in preclinical studies.
Katie Engleman, 1AB